Annette Pluetschow

No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group

Karolin Behringer, L. Wildt, Horst Mueller et al. · Annals of Oncology · 2010 · 165 citations · Full text

Lymphoid Neoplasia, Contraception, Hormonal Contraceptive +13

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

Dennis A. Eichenauer, Michael Fuchs, Annette Pluetschow et al. · Blood · 2011 · 117 citations · Full text

ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials

Boris Böll, Helen Görgen, Michael Fuchs et al. · Journal of Clinical Oncology · 2013 · 109 citations · Full text

Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG).

Andreas Engert, Annette Pluetschow, Hans Theodor Eich et al. · Blood · 2005 · 24 citations

Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Andreas Engert, Peter Borchmann, Annette Pluetschow et al. · Blood · 2010 · 23 citations